Paul Kwon Net Worth

The estimated Net Worth of Paul Kwon is at least $108 mil dollars as of 11 December 2019. Paul Kwon owns over 80,300 units of Menlo Therapeutics stock worth over $108,405 and over the last 7 years Paul sold MNLO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Kwon MNLO stock SEC Form 4 insiders trading

Paul has made over 1 trades of the Menlo Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Paul exercised 80,300 units of MNLO stock worth $108,405 on 11 December 2019.

The largest trade Paul's ever made was exercising 80,300 units of Menlo Therapeutics stock on 11 December 2019 worth over $108,405. On average, Paul trades about 20,075 units every 0 days since 2018. As of 11 December 2019 Paul still owns at least 80,300 units of Menlo Therapeutics stock.

You can see the complete history of Paul Kwon stock trades at the bottom of the page.

What's Paul Kwon's mailing address?

Paul's mailing address filed with the SEC is 200 Cardinal Way 2ND FLOOR, Redwood City, CA 94063, USA.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr y Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Complete history of Paul Kwon stock trades at Menlo Therapeutics

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer